{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:11:32Z","timestamp":1787166692870,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-022-03238-x","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T16:20:20Z","timestamp":1668010820000},"page":"537-544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Metabolic effects of dopamine-agonists treatment among patients with prolactinomas"],"prefix":"10.1007","volume":"79","author":[{"given":"Maryam","family":"Kabootari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habibeh","family":"Shirmohammadli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Golgiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedarad","family":"Mosalamiaghili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Khajavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamideh","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"3238_CR1","doi-asserted-by":"crossref","unstructured":"M.P. Gillam, M.E. Molitch, G. Lombardi, A. Colao. Advances in the treatment of prolactinomas. 27(5), 485\u2013534 (2006)","DOI":"10.1210\/er.2005-9998"},{"issue":"6","key":"3238_CR2","first-page":"440","volume":"16","author":"BA Do\u011fan","year":"2016","unstructured":"B.A. Do\u011fan, A. Ardu\u00e7, M.M. Tuna, N.I. Nas\u0131ro\u011flu, S. I\u015f\u0131k, D. Berker et al. Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma. Anatol. J. Cardiol. 16(6), 440 (2016)","journal-title":"Anatol. J. Cardiol."},{"issue":"18","key":"3238_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/eurheartj\/ehs233","volume":"35","author":"R Haring","year":"2014","unstructured":"R. Haring, N. Friedrich, H. V\u00f6lzke, R.S. Vasan, S.B. Felix, M. D\u00f6rr et al. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur. Heart J. 35(18), 1215\u20131221 (2014)","journal-title":"Eur. Heart J."},{"issue":"4","key":"3238_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.15557\/PiMR.2021.0046","volume":"17","author":"A Jurek","year":"2021","unstructured":"A. Jurek, P. Krzesi\u0144ski, G. Gielerak, B. Uzi\u0119b\u0142o-\u017byczkowska, P. Witek, G. Zieli\u0144ski et al. Prolactinoma and cardiovascular diseases\u2013an interdisciplinary problem. Pediatr. Med Rodz. 2021 17(4), 294\u2013298 (2021). https:\/\/doi.org\/10.15557\/PiMR.2021.0046","journal-title":"Pediatr. Med Rodz. 2021"},{"issue":"4","key":"3238_CR5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2265.2006.02469.x","volume":"64","author":"O Serri","year":"2006","unstructured":"O. Serri, L. Li, J.C. Mamputu, M.C. Beauchamp, F. Maingrette, G. Renier, The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin. Endocrinol. 64(4), 366\u2013370 (2006)","journal-title":"Clin. Endocrinol."},{"issue":"4","key":"3238_CR6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/oby.2010.150","volume":"19","author":"CM Silva","year":"2011","unstructured":"C.M. Silva, F.R. Barbosa, G.A. Lima, L. Warszawski, R. Fontes, R.C. Domingues et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obes. (Silver Spring) 19(4), 800\u2013805 (2011)","journal-title":"Obes. (Silver Spring)"},{"issue":"06","key":"3238_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1055\/s-0043-107243","volume":"49","author":"J Krogh","year":"2017","unstructured":"J. Krogh, C. Selmer, C. Torp-Pedersen, G.H. Gislason, C. Kistorp, Hyperprolactinemia and the association with all-cause mortality and cardiovascular mortality. Horm. Metab. Res. 49(06), 411\u2013417 (2017)","journal-title":"Horm. Metab. Res."},{"issue":"2","key":"3238_CR8","doi-asserted-by":"publisher","first-page":"e002640","DOI":"10.1161\/JAHA.115.002640","volume":"5","author":"KE Therkelsen","year":"2016","unstructured":"K.E. Therkelsen, T.M. Abraham, A. Pedley, J.M. Massaro, P. Sutherland, U. Hoffmann et al. Association between prolactin and incidence of cardiovascular risk factors in the Framingham Heart Study. J. Am. Heart Assoc. 5(2), e002640 (2016)","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"3238_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12020-012-9857-y","volume":"44","author":"SS Inancli","year":"2013","unstructured":"S.S. Inancli, A. Usluogullari, Y. Ustu, S. Caner, A.A. Tam, R. Ersoy et al. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine 44(1), 193\u2013199 (2013)","journal-title":"Endocrine"},{"issue":"3","key":"3238_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1530\/eje.0.1490187","volume":"149","author":"D Yavuz","year":"2003","unstructured":"D. Yavuz, O. Deyneli, I. Akpinar, E. Yildiz, H. Gozu, O. Sezgin et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur. J. Endocrinol. 149(3), 187\u2013194 (2003)","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"3238_CR11","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1530\/EC-19-0286","volume":"8","author":"S Byberg","year":"2019","unstructured":"S. Byberg, J. Futtrup, M. Andreassen, J. Krogh, Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis. Endocr. Connect. 8(10), 1395\u20131404 (2019)","journal-title":"Endocr. Connect."},{"issue":"16","key":"3238_CR12","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 120(16), 1640\u20131645 (2009)","journal-title":"Circulation"},{"key":"3238_CR13","unstructured":"F. Azizi, D. Khalili, H. Aghajani, A. Esteghamati, F. Hosseinpanah, A. Delavari et al. Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity. Archives of Iranian Medicine. 13(3) (2010)"},{"issue":"2","key":"3238_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(2), 273\u2013288 (2011)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"3238_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-015-0094-4","volume":"7","author":"NA Pala","year":"2015","unstructured":"N.A. Pala, B.A. Laway, R.A. Misgar, R.A. Dar, Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol. Metab. Syndr. 7(1), 1\u20136 (2015)","journal-title":"Diabetol. Metab. Syndr."},{"issue":"2","key":"3238_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4103\/2230-8210.176346","volume":"20","author":"NA Pala","year":"2016","unstructured":"N.A. Pala, B.A. Laway, R.A. Misgar, Z.A. Shah, T.A. Gojwari, T.A. Dar, Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: Response to treatment with cabergoline. Indian J. Endocrinol. Metab. 20(2), 177 (2016)","journal-title":"Indian J. Endocrinol. Metab."},{"issue":"2","key":"3238_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/17446651.2018.1434412","volume":"13","author":"RS Auriemma","year":"2018","unstructured":"R.S. Auriemma, D. De Alcubierre, R. Pirchio, R. Pivonello, A. Colao, The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev. Endocrinol. Metab. 13(2), 99\u2013106 (2018)","journal-title":"Expert Rev. Endocrinol. Metab."},{"issue":"1","key":"3238_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000371851","volume":"101","author":"RS Auriemma","year":"2015","unstructured":"R.S. Auriemma, M. Galdiero, P. Vitale, L. Granieri, F.L. Calzo, C. Salzano et al. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology 101(1), 66\u201381 (2015)","journal-title":"Neuroendocrinology"},{"issue":"3","key":"3238_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11102-010-0277-9","volume":"14","author":"K Berinder","year":"2011","unstructured":"K. Berinder, T. Nystr\u00f6m, C. H\u00f6ybye, K. Hall, A.-L. Hulting, Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14(3), 199\u2013207 (2011)","journal-title":"Pituitary"},{"issue":"6","key":"3238_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/cen.12204","volume":"79","author":"A Ciresi","year":"2013","unstructured":"A. Ciresi, M.C. Amato, V. Guarnotta, F. Lo Castro, C. Giordano, Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin. Endocrinol. 79(6), 84\u2013852 (2013)","journal-title":"Clin. Endocrinol."},{"issue":"1","key":"3238_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11011-016-9882-2","volume":"32","author":"V Schwetz","year":"2017","unstructured":"V. Schwetz, R. Librizzi, C. Trummer, G. Theiler, C. Stiegler, T.R. Pieber et al. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas. Metab. Brain Dis. 32(1), 155\u2013161 (2017)","journal-title":"Metab. Brain Dis."},{"issue":"4","key":"3238_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000357810","volume":"98","author":"RS Auriemma","year":"2013","unstructured":"R.S. Auriemma, L. Granieri, M. Galdiero, C. Simeoli, Y. Perone, P. Vitale et al. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology 98(4), 299\u2013310 (2013)","journal-title":"Neuroendocrinology"},{"issue":"1","key":"3238_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-021-00733-6","volume":"21","author":"AS Posawetz","year":"2021","unstructured":"A.S. Posawetz, C. Trummer, M. Pandis, F. Aberer, T.R. Pieber, B. Obermayer-Pietsch et al. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study. BMC Endocr. Disord. 21(1), 1\u20139 (2021)","journal-title":"BMC Endocr. Disord."},{"issue":"1","key":"3238_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/dom.14183","volume":"23","author":"IB Andersen","year":"2021","unstructured":"I.B. Andersen, M. Andreassen, J. Krogh, The effect of dopamine agonists on metabolic variables in adults with type 2 diabetes: a systematic review with meta analysis and trial sequential analysis of randomized clinical trials. Diabetes, Obes. Metab. 23(1), 58\u201367 (2021)","journal-title":"Diabetes, Obes. Metab."},{"issue":"1","key":"3238_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pcd.2015.10.008","volume":"10","author":"E Lamos","year":"2016","unstructured":"E. Lamos, D. Levitt, K. Munir, A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters. Prim. Care Diabetes 10(1), 60\u201365 (2016)","journal-title":"Prim. Care Diabetes"},{"issue":"4","key":"3238_CR26","first-page":"390","volume":"67","author":"SM Taghavi","year":"2012","unstructured":"S.M. Taghavi, S.S. Fatemi, H. Rokni, Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure. Med. J. Malays. 67(4), 390\u2013392 (2012)","journal-title":"Med. J. Malays."},{"issue":"40","key":"3238_CR27","doi-asserted-by":"publisher","first-page":"e4818","DOI":"10.1097\/MD.0000000000004818","volume":"95","author":"A Bahar","year":"2016","unstructured":"A. Bahar, Z. Kashi, E. Daneshpour, O. Akha, S. Ala, Effects of cabergoline on blood glucose levels in type 2 diabetic patients: a double-blind controlled clinical trial. Medicine 95(40), e4818 (2016). https:\/\/doi.org\/10.1097\/MD.0000000000004818","journal-title":"Medicine"},{"issue":"2","key":"3238_CR28","first-page":"OC01","volume":"14","author":"A Aliasgarzadeh","year":"2020","unstructured":"A. Aliasgarzadeh, S. Karimiavval, J. Houshyar, M. Gojazadeh, A. Hadi, Evaluating the effect of cabergoline on glycaemic control of patients with type 2 diabetes mellitus: a randomised controlled trial. J. Clin. Diagnostic Res. 14(2), OC01\u2013OC04 (2020)","journal-title":"J. Clin. Diagnostic Res."},{"issue":"3","key":"3238_CR29","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/j.diabres.2011.05.030","volume":"93","author":"ACJ Vasques","year":"2011","unstructured":"A.C.J. Vasques, F.S. Novaes, M.D.S. de Oliveira, J.R.M. Souza, A. Yamanaka, J.C. Pareja et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res. Clin. Pract. 93(3), e98\u2013e100 (2011)","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"1","key":"3238_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"K Zhang","year":"2017","unstructured":"K. Zhang, Y. Chen, L. Liu, M. Lu, J. Cheng, F. Gao et al. The Triglycerides and Glucose Index rather than HOMA-IR is more associated with Hypogonadism in Chinese men. Sci. Rep. 7(1), 1\u20137 (2017)","journal-title":"Sci. Rep."},{"issue":"7","key":"3238_CR31","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1210\/jc.2010-0288","volume":"95","author":"F Guerrero-Romero","year":"2010","unstructured":"F. Guerrero-Romero, L.E. Simental-Mend\u00eda, M. Gonza\u0301lez-Ortiz, E. Mart\u00ednez-Abundis, M.G. Ramos-Zavala, S.O. Herna\u0301ndez-Gonza\u0301lez et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison euglycemic-hyperinsulinemic clamp. J. Clin. Endocrinol. Metab. 95(7), 3347\u20133351 (2010)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"3238_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/met.2008.0034","volume":"6","author":"LE Simental-Mend\u00eda","year":"2008","unstructured":"L.E. Simental-Mend\u00eda, M. Rodr\u00edguez-Mor\u00e1n, F. Guerrero-Romero, The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab. Syndr. Relat. Disord. 6(4), 299\u2013304 (2008)","journal-title":"Metab. Syndr. Relat. Disord."},{"issue":"2","key":"3238_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/eci.12583","volume":"46","author":"L S\u00e1nchez\u2010\u00cd\u00f1igo","year":"2016","unstructured":"L. S\u00e1nchez\u2010\u00cd\u00f1igo, D. Navarro\u2010Gonz\u00e1lez, A. Fern\u00e1ndez\u2010Montero, J. Pastrana\u2010Delgado, J.A. Mart\u00ednez, The TyG index may predict the development of cardiovascular events. Eur. J. Clin. Invest. 46(2), 189\u2013197 (2016)","journal-title":"Eur. J. Clin. Invest."},{"issue":"1","key":"3238_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"S Li","year":"2019","unstructured":"S. Li, B. Guo, H. Chen, Z. Shi, Y. Li, Q. Tian et al. The role of the triglyceride (triacylglycerol) glucose index in the development of cardiovascular events: a retrospective cohort analysis. Sci. Rep. 9(1), 1\u20139 (2019)","journal-title":"Sci. Rep."},{"issue":"1","key":"3238_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-018-0376-8","volume":"10","author":"SH Khan","year":"2018","unstructured":"S.H. Khan, F. Sobia, N.K. Niazi, S.M. Manzoor, N. Fazal, F. Ahmad et al. Metabolic clustering of risk factors: evaluation of Triglyceride-glucose index (TyG index) for evaluation of insulin resistace. Diabetol. Metab. Syndr. 10(1), 1\u20138 (2018)","journal-title":"Diabetol. Metab. Syndr."},{"issue":"11","key":"3238_CR36","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S2213-8587(19)30179-2","volume":"7","author":"F Azizi","year":"2019","unstructured":"F. Azizi, F. Hadaegh, F. Hosseinpanah, P. Mirmiran, A. Amouzegar, H. Abdi et al. Metabolic health in the Middle East and North Africa. Lancet Diabetes Endocrinol. 7(11), 866\u2013879 (2019)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"16","key":"3238_CR37","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 120(16), 1640\u20131645 (2009)","journal-title":"Circulation"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03238-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03238-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03238-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T10:01:38Z","timestamp":1701338498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03238-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["3238"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03238-x","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"21 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the Golestan University of Medical Science (Protocol no. IR.GOUMS.REC.1398.300) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent for publication was obtained from patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}